Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer

NCT05016349 is registered in ClinicalTrials.gov with Mahmoud Ramadan mohamed Elkazzaz as lead sponsor.

NCT NCT05016349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05016349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer
Lead sponsor
Mahmoud Ramadan mohamed Elkazzaz
Phase
Phase 3
Overall status
Unknown status
Start date
August 31, 2021
Completion date
December 31, 2021
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female